UAB study shows investigational drug may treat biliary cancers

April 15, 2008

BIRMINGHAM, Ala. -- Laboratory studies by University of Alabama at Birmingham (UAB) researchers have shown that the investigational drug triphendiol (NV-196) causes cell death in pancreatic and bile duct cancer cell lines, slows tumor growth and sensitizes tumors to chemotherapy treatments.

The findings were presented April 13 by Ewan Tytler, Ph.D., assistant professor in the UAB Department of Surgery, Gastrointestinal Section, at the annual meeting of the American Association for Cancer Research (AACR).

Tytler and his colleagues assessed the potential of triphendiol as a treatment for pancreatic adenocarcinoma using three representative cell lines. Triphendiol induced cell death in all three cell lines and pre-treating the cell lines with triphendiol increased the effectiveness of chemotherapy. Animal model studies showed that triphendiol in combination with chemotherapy inhibited tumor growth more effectively than each drug alone.

"In our laboratory studies, triphendiol is more potent at inducing cell death in pancreatic and bile duct cancer cells compared to the chemotherapy drug gemcitabine alone at up to 10-fold lower concentrations," Tytler said. "Of course, there is still much work to be done before this could become a treatment protocol for cancer patients but our findings are promising and validate the continued development of triphendiol as a possible pancreatic cancer therapy."

Triphendiol is being developed by Marshall Edwards Inc., as a treatment for late stage pancreatic and gall bladder cancer and recently received orphan drug status by the U.S. Food and Drug Administration. Triphendiol has been licensed by Novogen to Marshall Edwards Inc., who funded Tytler's study.

Tytler said that there is an urgent need for new pancreatic cancer treatments because fewer than 20 percent of patients are candidates for surgery. Current treatment is limited to chemotherapy, which is not always effective, as most tumors are resistant to or become resistant to the commonly used chemotherapy drug for pancreatic tumors, gemcitabine.
-end-
UAB research associate Xiaohong Wang, M.D. and UAB professor of Surgery J. Anthony Thompson, Ph.D., are co-authors of the study.

- www.uab.edu/news -

University of Alabama at Birmingham

Related Chemotherapy Articles from Brightsurf:

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Starved cancer cells became more sensitive to chemotherapy
By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

Male fertility after chemotherapy: New questions raised
Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

Read More: Chemotherapy News and Chemotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.